volkow204

8/8/2019 Volkow204

1/50

Directors Report to theNational Advisory Council

on Drug Abuse

Directors Report to theNational Advisory Council

on Drug Abuse

February 12, 2004February 12, 2004

8/8/2019 Volkow204

2/50

Recent NIDA StaffAppointments/Changes


Richard A. Millstein, J.D.

Acting Deputy DirectorNIH John E. Fogarty International Centerfor Advanced Study in the Health Sciences

Richard A. Millstein, J.D.

Acting Deputy DirectorNIH John E. Fogarty International Centerfor Advanced Study in the Health Sciences

8/8/2019 Volkow204

3/50



Timothy P. Condon, Ph.D.Deputy Director, NIDA

Timothy P. Condon, Ph.D.Deputy Director, NIDA

andand

Director, OSPCDirector, OSPC

NIDA

8/8/2019 Volkow204

4/50

Directors Report to theNational Advisory Council on Drug Abuse

Directors Report to theNational Advisory Council on Drug Abuse

Science HighlightsScience Highlights

Whats New at NIH?Whats New at NIH?

Budget UpdateBudget Update

Recent NIDA ActivitiesRecent NIDA Activities

FY 2004 and BeyondFY 2004 and Beyond

8/8/2019 Volkow204

5/50

Whats New at NIH?Whats New at NIH?

8/8/2019 Volkow204

6/50

NIH Central Steering CommitteeNIH Central Steering Committee

Rotating Members (three year terms):

Francis Collins Genome Research Institute Richard Hodes Aging Stephen Katz Arthritis Musculoskeletal & Skin Diseases Donald Lindberg National Library of Medicine

Stephen Straus Complementary & Alternative Medicine Larry Tabak Dental & Craniofacial Research Nora Volkow NIDA

Rotating Members (three year terms):

Francis Collins Genome Research Institute Richard Hodes Aging Stephen Katz Arthritis Musculoskeletal & Skin Diseases Donald Lindberg National Library of Medicine

Stephen Straus Complementary & Alternative Medicine Larry Tabak Dental & Craniofacial Research Nora Volkow NIDA

Permanent Members (three largest institutes):

Andrew von Eschenbach National Cancer Institute Barbara Albin National Heart, Lung and Blood Institute Anthony Fauci National Institute of Allergy and Infectious Diseases

Permanent Members (three largest institutes):

Andrew von Eschenbach National Cancer Institute Barbara Albin National Heart, Lung and Blood Institute Anthony Fauci National Institute of Allergy and Infectious Diseases

8/8/2019 Volkow204

7/50

Enhancing the Vitality of theNational Institutes of Health:

Organizational Change toMeet New Challenges

Enhancing the Vitality of theNational Institutes of Health:

Organizational Change toMeet New Challenges

Report by National Research Council and IoM

Create a public process for considering proposed changes in the numberof NIH institutes or centers.

Enhance and increase trans-NIH strategic planning and funding.

Create a Directors Special Projects Program to support high risk, highpotential payoff research.

Promote innovation and risk-taking in intramural research.

2.

4.

7.

8.

8/8/2019 Volkow204

8/50

THE NIH ROADMAPTHE NIH ROADMAP

An Agency-Wide Effort To Identify the

Critical Roadblocks and Knowledge GapsThat Constrain Rapid Advancesin Biomedical Research Progress

Molecular Libraries and Imaging Research Teams of the Future High-Risk Research

Private-Public Partnerships Re-engineering the Clinical Research Enterprise

Molecular Libraries and Imaging Research Teams of the Future High-Risk Research

Private-Public Partnerships Re-engineering the Clinical Research Enterprise

8/8/2019 Volkow204

9/50

What Has NIDA Done to Ensure Participationof Substance Abuse Researchers

on the NIH Roadmap?

What Has NIDA Done to Ensure Participationof Substance Abuse Researchers

on the NIH Roadmap?

Dr. Condon named NIDAs representative forthe Roadmap

Program officers have contacted potential grantees toencourage them to submit grants for Roadmap RFAs

Created a page on NIDA website that highlightsopportunities from the roadmap relevant to NIH

grantees

Periodic staff meetings with NIDA Director to reviewprogress and plan strategies

Dr. Condon named NIDAs representative forthe Roadmap

Program officers have contacted potential grantees toencourage them to submit grants for Roadmap RFAs

Created a page on NIDA website that highlightsopportunities from the roadmap relevant to NIH

grantees

Periodic staff meetings with NIDA Director to reviewprogress and plan strategies

8/8/2019 Volkow204

10/50

Ethics Issues at NIHEthics Issues at NIH

New Initiatives to Strenthen the NIH Ethics Program:New Initiatives to Strenthen the NIH Ethics Program:

Concern by congress that there may be conflict between the rol

of NIH directors and of NIH scientists and private partnership

Concern by congress that there may be conflict between the rol

of NIH directors and of NIH scientists and private partnership

Raynard S. Kington, M.D., Ph.D., NIH Deputy Director, appointedas Deputy Ethics Counselor (DEC) for the NIH and the Office of theDirector, NIH

Blue Ribbon Panel established to review current NIH Ethics policies

NIH Ethics Advisory Committee (NEAC) established(composed of members of the NIH community)

Raynard S. Kington, M.D., Ph.D., NIH Deputy Director, appointedas Deputy Ethics Counselor (DEC) for the NIH and the Office of theDirector, NIH

Blue Ribbon Panel established to review current NIH Ethics policies

NIH Ethics Advisory Committee (NEAC) established(composed of members of the NIH community)

8/8/2019 Volkow204

11/50

NIH Consolidation and Centralization Activities(occurring through several approaches)

Outsourcing studies:

NIH competes against outside contractorsExtramural Support was studied last year656 FTEs now in ICs (22 in NIDA) will be centralized into a new NIH Office theMEO Most Efficient Organization -- Implementation Date: April 1, 2004.

Outsourcing studies:NIH competes against outside contractors

Extramural Support was studied last year656 FTEs now in ICs (22 in NIDA) will be centralized into a new NIH Office theMEO Most Efficient Organization -- Implementation Date: April 1, 2004.

NIH Administrative Restructuring Plan ARAC

(Administrative Restructuring and Advisory Committee)Consolidation of functions in several areas including:Personnel, Grants Management, Budget, Acquisitions, Information Technology,Facilities, Financial Maagement and EEO

NIH Administrative Restructuring Plan ARAC

(Administrative Restructuring and Advisory Committee)Consolidation of functions in several areas including:Personnel, Grants Management, Budget, Acquisitions, Information Technology,Facilities, Financial Maagement and EEO

Harmonization of and accountability for achieving both corporate NIH objectiveand IC-specific objectives Looking at Dual Reporting for senior IC staffHarmonization of and accountability for achieving both corporate NIH objectivesand IC-specific objectives Looking at Dual Reporting for senior IC staff

FTE Ceiling imposed to limit the number of NIH employees at each institute;NIDAs is 373 in FY04FTE Ceiling imposed to limit the number of NIH employees at each institute;NIDAs is 373 in FY04

8/8/2019 Volkow204

12/50

Budget UpdateBudget Update

8/8/2019 Volkow204

13/50

NIDA BUDGETNIDA BUDGET(Thousands)(Thousands)

Increase OverIncrease Over

Prior YearPrior Year

Increase OverIncrease Over

Prior YearPrior Year

AIDSAIDSAIDSAIDS

TOTALTOTALTOTALTOTAL

NonAIDSNonAIDSNonAIDSNonAIDS $659,431$659,431

$301,514$301,514

2003Actual2003

Actual

$960,945$960,945

+8.2%+8.2%

$677,808$677,808

$312,979$312,979

2004Estimate

2004Estimate

$990,787$990,787

+3.0%+3.0%

$703,328$703,328

$315,732$315,732

2005P.B.

2005P.B.

$1,019,060$1,019,060

+2.9%+2.9%

8/8/2019 Volkow204

14/50

Recent NIDA ActivitiesRecent NIDA Activities

8/8/2019 Volkow204

15/50

Treatment Interventions Treatment Interventions

Prevention Research (Children and Adolescents) Prevention Research (Children and Adolescents) Novel Approaches to Phenotyping Drug Abuse (RFA) Behavioral and Cognitive Processes in Adolescent Drug Abuse (RF Animal Models of Adolescent Drug Abuse (RFA) Prevention Research for the Transition to Adulthood (RFA)

Consequences of Marijuana Use on the Developing Brain (RFA)

Novel Approaches to Phenotyping Drug Abuse (RFA) Behavioral and Cognitive Processes in Adolescent Drug Abuse (RF Animal Models of Adolescent Drug Abuse (RFA) Prevention Research for the Transition to Adulthood (RFA)

Consequences ofMarijuana Use on the Developing Brain (RFA)

New NIDA PAs and RFAsNew NIDA PAs and RFAs

Medications Development for Cannabis-Related Disorders (RFA) Medications Development for Cannabis-Related Disorders (RFA)

8/8/2019 Volkow204

16/50

Training Training

HIV/HCV HIV/HCV Drug Abuse Aspects of HIV/AIDS and Other Infections (PA) HIV/AIDS and Other Infections Among Drug Users in the Crimin

Justice System (RFA) Targeted Integrative Research in Drug Abuse and HIV/AIDS in

Pregnancy (RFA)

Drug Abuse Aspects ofHIV/AIDS and Other Infections (PA) HIV/AIDS and Other Infections Among Drug Users in the Crimin

Justice System (RFA) Targeted Integrative Research in Drug Abuse and HIV/AIDS in

Pregnancy (RFA)

New NIDA PAs and RFAsNew NIDA PAs and RFAs

Research Education Grants in Drug Abuse and Addiction (PA) Research Education Grants in Drug Abuse and Addiction (PA)

8/8/2019 Volkow204

17/50

PAs and RFA With Other NIH ComponentsPAs and RFA With Other NIH Components

8 New PAs and4 New RFAs (Totaling $9.8 Million)

8 New PAs and4 New RFAs (Totaling $9.8 Million)

Focus predominantly on:

CO-MORBIDITYMental illness

Alcoholism

HIV

Focus predominantly on:

CO-MORBIDITYMental illness

Alcoholism

HIV

8/8/2019 Volkow204

18/50

NIDA/SAMHSAAddiction Technology Transfer Center (ATTC)

Blending Initiative

NIDA/SAMHSAAddiction Technology Transfer Center (ATTC)

Blending Initiative

Members of CSATs ATTC Network+

NIDA Researchers

Members of CSATs ATTC Network+

NIDA Researchers

BLENDING TEAMSBLENDING TEAMS

Buprenorphine awarenesstraining and materials fornon-physicians in the drug

abuse and addiction field

Buprenorphine awarenesstraining and materials fornon-physicians in the drug

abuse and addiction field

Training materials andproducts to help programmanagers, administratorsand policy makers use

Addiction Severity Index (ASI)results for management andprogram planning decisions

Training materials andproducts to help programmanagers, administratorsand policy makers use

Addiction Severity Index (ASI)results for management andprogram planning decisions

8/8/2019 Volkow204

19/50

Highlights of Recent

Meetings and Events

Highlights of Recent

Meetings and Events

S i t f N i A l M tiS i t f N i A l M ti

8/8/2019 Volkow204

20/50

Society for Neuroscience Annual MeetingSociety for Neuroscience Annual Meeting

2002 ~ 471 of 13, 3932003 ~ 576 of 16,1552002 ~ 471 of 13, 3932003 ~ 576 of 16,155

~~~~

Growth in Drug Abuse-Related PresentationsGrowth in Drug Abuse-Related Presentations

NIDA-Sponsored Mini-ConventionNIDA-Sponsored Mini-Convention

Opening Plenary Lecture

THE ADDICTED HUMAN BRAIN

Nora D. Volkow, M.D., Director, NIDA

Opening Plenary Lecture

THE ADDICTED HUMAN BRAIN

Nora D. Volkow, M.D., Director, NIDA

8/8/2019 Volkow204

21/50

8/8/2019 Volkow204

22/50

We Recently Released Our NewWebsite for Teens!

8/8/2019 Volkow204

23/50

.. ....

Educational Seminar for Primary Health Care ProvidersCo-sponsored by NIDA and the Sheppard Pratt Health SystemSheppard Pratt Conference CenterBaltimore MDDecember 17, 2003

Tent at New Years Eve Spectacular(widely attended alcohol- drug- and smoke-free community event)Co-sponsored by NIDA in collaboration with the Maryland Chapter

of the American Academy of Pediatrics, coalition partners andcorporate sponsorsBaltimore MDDecember 31, 2003

Educational Seminar for Primary Health Care ProvidersCo-sponsored by NIDA and the Sheppard Pratt Health SystemSheppard Pratt Conference CenterBaltimore MDDecember 17, 2003

Tent at New Years Eve Spectacular(widely attended alcohol- drug- and smoke-free community event)Co-sponsored by NIDA in collaboration with the Maryland Chapter

of the American Academy of Pediatrics, coalition partners andcorporate sponsorsBaltimore MDDecember 31, 2003

NIDAsPrimary Healthcare

Outreach Initiative

NIDAsPrimary Healthcare

Outreach Initiative

8/8/2019 Volkow204

24/50

Science HighlightsScience Highlights

Percent of Students Reporting PastPercent of Students Reporting Past

8/8/2019 Volkow204

25/50

Percent of Students Reporting PastMonth Use of Any Illicit Drug

Percent of Students Reporting PastMonth Use of Any Illicit Drug

19.419.4

18.218.2

17.317.3

1616

1717

1818

1919

2020

20012001 20022002 2003200311% Decline

2001 to 2003

11% Decline

2001 to 2003Monitoring the Future Study 2003Monitoring the Future Study 2003

GREAT NEWS!!

Percent of Students Reporting Abuse ofPercent of Students Reporting Abuse of

8/8/2019 Volkow204

26/50

Percent of Students Reporting Abuse of

Pain Killers in Past 12 Months in 2003

Percent of Students Reporting Abuse of

Pain Killers in Past 12 Months in 2003

1.71.72.82.8

3.63.6

7.27.2

4.54.5

10.510.5

0.00.0

2.02.0

4.04.0

6.06.0

8.08.0

10.010.0

12.012.0

OxycontinOxycontin VicodinVicodin

8th Grade8th Grade

10th Grade10th Grade

12th Grade12th Grade

Source: Monitoring the Future Study, 200Source: Monitoring the Future Study, 200

Perce

nt

Perc e

nt

WORRISOME NEWS

Numbers of New Abusers ofNumbers of New Abusers of

8/8/2019 Volkow204

27/50

Numbers ofNewAbusers ofPrescription Drugs: 1965-2001

Numbers ofNewAbusers ofPrescription Drugs: 1965-2001

Source: SAMHSA, 2002 NSDUHSource: SAMHSA, 2002 NSDUH

8/8/2019 Volkow204

28/50

Millions of Americans Abuse Prescription DrugsMillions of Americans Abuse Prescription Drugs

SedativesSedativesStimulantsStimulants00

0.50.5

11

1.51.522

2.52.5

33

Millionsof

Am

ericans

Millio

nsof

Americans

3.53.5

44

4.54.5

1.2 million1.2 million



Use of Prescription Drugs for Non-Medical Purposes2002 National Survey on Drug Use and Health

Use of Prescription Drugs for Non-Medical Purposes2002 National Survey on Drug Use and Health

Pain RelieversPain Relievers

Wh H h Ab f P i iWh H th Ab f P i ti

8/8/2019 Volkow204

29/50

Why Has the Abuse of Prescription

Drugs Increased?

Why Has the Abuse of Prescription

Drugs Increased?

Increasing numbers of prescriptions(greater availability)

Attention by the media and advertising(television and newspaper)

Easier access(e.g. internet availability)

Improper knowledge and monitoring

(adverse effects go unrecognized)

Increasing numbers of prescriptions(greater availability)

Attention by the media and advertising(television and newspaper)

Easier access(e.g. internet availability)

Improper knowledge and monitoring

(adverse effects go unrecognized)

A P i ti I E RA P i ti I E R

8/8/2019 Volkow204

30/50

As Prescriptions Increase Emergency RoomVisits For Non-Medical Abuse

Have Also Increased

As Prescriptions Increase Emergency RoomVisits For Non-Medical Abuse

Have Also Increased

Num

berofPr e

scriptions(in

1000s )

Numbe r

ofPrescript i

ons(in1000s )

0

10000

20000

30000

4000050000

60000

70000

80000

1994

1995

1996

1997 1

998

1999

2000

20010

6000

12000

18000

24000

E D

M e n

tion

s

Source: SAMHSA, DAWN, 2002Source: SAMHSA, DAWN, 2002

HydrocodoneHydrocodone

OxycodoneOxycodone

prescriptionsprescriptions

prescriptionprescription

emergencyemergency

emergencyemergency

I d M di Att tiIncreased Media Attention

8/8/2019 Volkow204

31/50

Increased Media AttentionIncreased Media Attention

Availability on the InternetAvailability on the Internet
http://images.google.com/imgres?imgurl=www.menstuff.org/books/covers2/time.gif&imgrefurl=http://www.menstuff.org/issues/byissue/healthgeneral.html&hl=en&h=228&w=172&start=83&prev=/images%3Fq%3Dritalin%26start%3D80%26svnum%3D10%26hl%3Den%26lr%3D%26ie%3DUTF-8%26oe%3DUTF-8%26sa%3DN

8/8/2019 Volkow204

32/50

Availability on the Internet

Delivered in the Privacy of your Home

Availability on the Internet

Delivered in the Privacy of your Home

Some reasons wyou should consid

using thispharmacy

Noprescriptionrequired!

Some reasons wyou should consid

using thispharmacy

Noprescriptionrequired!

8/8/2019 Volkow204

33/50

Other Reasons for ConcernOther Reasons for Concern

These drugs can have serious medical consequences i.elethal overdose with pain killers, psychosis withstimulant medications

Misuse in elderly populations who are particularlysensitive to adverse medical reactions

Increase use by adolescents of drugs that may have longterm effects in brain development

These drugs can have serious medical consequences i.elethal overdose with pain killers, psychosis withstimulant medications

Misuse in elderly populations who are particularlysensitive to adverse medical reactions

Increase use by adolescents of drugs that may have longterm effects in brain development

8/8/2019 Volkow204

34/50

How Does NIDAs Science Help

Fight Prescription Drug Abuse?

How Does NIDAs Science Help

Fight Prescription Drug Abuse?

Continue Research on Prescription Drugs andContinue Research on Prescription Drugs and

8/8/2019 Volkow204

35/50

p gon Treatment and Prevention

p gon Treatment and Prevention

When analgesics are injected

they are much more addictive

than when taken orally; hence

formulations that can interferewith the drug effects if injected

would decrease its diversion and

abuse

When analgesics are injected

they are much more addictive

than when taken orally; hence

formulations that can interferewith the drug effects if injected

would decrease its diversion and

abuse

8/8/2019 Volkow204

36/50

Development of Alternative Medications with noDevelopment of Alternative Medications with no

8/8/2019 Volkow204

37/50

pDrug Abuse Potential

pDrug Abuse Potential

8/8/2019 Volkow204

38/50

FY 2005 and BeyondFY 2005 and Beyond

NIDA FY 2005 InitiativesNIDA FY 2005 Initiatives

8/8/2019 Volkow204

39/50

Treatment Interventions Treatment Interventions

Prevention Research (Children and Adolescents)

Prevention Research (Children and Adolescents)Gene/Environment Interactions

Drug Exposure and the Developing Prenatal Brain

The Effects of Drugs of Abuse Across the Lifespan Impact of Drugs, Risky Behavior and HIV on Adolescent Brain

Drug Abuse Prevention and Treatment in Primary Care System Neurobiological Processes Underlying Co-morbidity

Gene/Environment Interactions

Drug Exposure and the Developing Prenatal Brain

The Effects of Drugs of Abuse Across the Lifespan Impact of Drugs, Risky Behavior and HIV on Adolescent Brain

Drug Abuse Prevention and Treatment in Primary Care System Neurobiological Processes Underlying Co-morbidity

NIDA FY 2005 InitiativesNIDA FY 2005 Initiatives

Pharmacogenetics and Medications Development Pharmacogenetics and Medications Development

Using Science to Improve Providers Knowledge and Skills Using Science to Improve Providers Knowledge and Skills Training Training

Systems and Translational ResearchSystems and Translational Research

8/8/2019 Volkow204

40/50

genomegenomeprotein expressionprotein expression

neuronal circuitsneuronal circuits

DRUGS OF ABUSEDRUGS OF ABUSE

socialsocial

behaviorbehavior

Systems and Translational ResearchApproaches in Addiction

Syste s a d a s at o a esea cApproaches in Addiction

Infrastructure Development and the Creation of Translational Research Centers Infrastructure Development and the Creation ofTranslational Research Centers

8/8/2019 Volkow204

41/50

Brain, Behavior & Health RoadmapBrain, Behavior & Health Roadmap

Brain, Behavior & Health InitiativeBrain, Behavior & Health Initiative

8/8/2019 Volkow204

42/50

,Mission

To develop the knowledge and the technologynecessary for understanding how the human brain

,Mission

To develop the knowledge and the technologynecessary for understanding how the human brain

works and molds human behavior, how genes and environmental factors mold its

development and function

how it changes throughout the lifespan

works and molds human behavior, how genes and environmental factors mold its

development and function

how it changes throughout the lifespan

This knowledge will help to better understandbrain diseases including ADDICTION, and to

develop strategies topromote optimal health

This knowledge will help to better understandbrain diseases including ADDICTION, and to

develop strategies topromote optimal health

FIRST MILESTONEC i h illFIRST MILESTONEC t t i th t ill

8/8/2019 Volkow204

43/50

Catalog ongoing projects that pertain

to a brain/behavior/health initiative

Identify scientific questions

Identify research areas of redundancy and areas thatneed to be developed

Identify technology or infrastructure that needs to be

developed

Optimize chances for integrating efforts across research

centers, institutes and agencies.

Catalog ongoing projects that pertain

to a brain/behavior/health initiative

Identify scientific questions

Identify research areas ofredundancy and areas that

need to be developed

Identify technology or infrastructure that needs to be

developed

Optimize chances for integrating efforts across research

centers, institutes and agencies.

Create a matrix that willCreate a matrix that will

8/8/2019 Volkow204

44/50

Matrix is based on a

systems approach

including

data from all levels ofbiology: genes, proteins

and their complexes,

cell, circuits, behavior

individual and social.

The matrix includes

projects in laboratory

animals and implicitly

addresses development

and gender.

Matrix is based on a

systems approach

including

data from all levels ofbiology: genes, proteins

and their complexes,

cell, circuits, behavior

individual and social.

The matrix includes

projects in laboratory

animals and implicitly

addresses development

and gender.

Social Network

BRAIN BEHAVIOR & HEALTH ROAD MAP

8/8/2019 Volkow204

45/50

2. Infrastructure& Projects

2. Infrastructure& Projects

3. Need forTechnology3. Need forTechnology

1. ScientificQuestion

1. ScientificQuestion

GENEGENE

PROTEINPROTEIN

CELLCELL

CIRCUITS/

PATHWAYS

CIRCUITS/

PATHWAYS

BEHAVIORBEHAVIOR

SOCIAL

NETWORKS

SOCIAL

NETWORKS

PAs and RFA With Other NIH ComponentsPAs and RFA With Other NIH Components

8/8/2019 Volkow204

46/50

p

National Cooperative Drug Discovery Groups for the Treatment of

Mood Disorders or Nicotine Addiction (NCDDG-MD/NA)Mechanisms of Alcoholic PancreatitisNeurotechnology Research, Development and EnhancementBioengineering Research PartnershipsHIV/AIDS, Severe Mental Illness and Homelessness (with NIAAA and NIMRuth L. Kirschstein National Research Service Awards for IndividualPredoctoral Fellows (F31)ELSI Regular Research Program (R01)ELSI Small Grant Research Program (R03)Transdisciplinary Tobacco Use Research Centers (with NCI and NIAAA)

Group Therapy for Individuals in Drug Abuse or Alcoholism TreatmenScreening and Intervention for Youth in Primary Care SettingsHIV/AIDS, Drug Use and Highly Vulnerable Youth: Targeting ResearcGaps (with NIMH)

National Cooperative Drug Discovery Groups for the Treatment of

Mood Disorders or Nicotine Addiction (NCDDG-MD/NA)Mechanisms of Alcoholic PancreatitisNeurotechnology Research, Development and EnhancementBioengineering Research PartnershipsHIV/AIDS, Severe Mental Illness and Homelessness(with NIAAA and NIMRuth L. Kirschstein National Research Service Awards for IndividualPredoctoral Fellows (F31)

ELSI Regular Research Program (R01)ELSI Small Grant Research Program (R03)Transdisciplinary Tobacco Use Research Centers(with NCI and NIAAA)

Group Therapy for Individuals in Drug Abuse or Alcoholism TreatmenScreening and Intervention for Youth in Primary Care SettingsHIV/AIDS, Drug Use and Highly Vulnerable Youth: Targeting ResearcGaps (with NIMH)

PAsPAs

RFAsRFAs

Monitoring the Future Study 2003P t f St d t R ti A Illi it D U

Monitoring the Future Study 2003P t f St d t R ti A Illi it D U

8/8/2019 Volkow204

47/50

Percent of Students ReportingAny Illicit Drug Usein Past Year, by Grade

Percent of Students ReportingAny Illicit Drug Usein Past Year, by Grade

8th Grade8th Grade

10th Grad10th Grad

12th Grad12th Grad

00

1010

2020

3030

4040

5050

6060

7575 7777 7979 8181 8383 8585 8787 8989 9191 9393 9595 9797 9999 0101 0303

Recent NIDA Staff Appointments/ChangesRecent NIDA Staff Appointments/Changes

8/8/2019 Volkow204

48/50

Steve Oversby, Psy.D. Medications Research Grants BranchJennifer Wong, Ph.D. Regulatory Affairs BranchSteve Oversby, Psy.D. Medications Research Grants BranchJennifer Wong, Ph.D. Regulatory Affairs Branch

Susan Weiss, Ph.D. Chief, Science Policy BranchRobin Mackar, M.P.H. Deputy Chief, Science Policy BranchGayathri Jeyarasasingam Science Policy Branch

Susan Weiss, Ph.D. Chief, Science Policy BranchRobin Mackar, M.P.H. Deputy Chief, Science Policy BranchGayathri Jeyarasasingam Science Policy Branch

Division of Treatment Research & DevelopmentDivision of Treatment Research & Development

Office of Science Policy and CommunicationOffice of Science Policy and Communication

Arnold Mills -- Acting Chief, Epidemiology Research Branch

Kevin Conway, Ph.D. Deputy Chief, Epidemiology Research BranchYonette Thomas, Ph.D. -- Deputy Chief, Epidemiology Research BranchJessica Campbell, Ph.D. Epidemiology Research BranchElizabeth Genexi, Ph.D. Prevention Research Branch

Arnold Mills -- Acting Chief, Epidemiology Research Branch

Kevin Conway, Ph.D. Deputy Chief, Epidemiology Research BranchYonette Thomas, Ph.D. -- Deputy Chief, Epidemiology Research BranchJessica Campbell, Ph.D. Epidemiology Research BranchElizabeth Genexi, Ph.D. Prevention Research Branch

Division of Epidemiology, Services and Prevention ResearchDivision of Epidemiology, Services and Prevention Research

Center on AIDS and Other Medical Consequences of Drug AbuseCenter on AIDS and Other Medical Consequences of Drug Abuse

Center for the Clinical Trials NetworkCenter for the Clinical Trials NetworkTheresa Montini, Ph.D.Arnaldo R. Quinones, M.D.Theresa Montini, Ph.D.Arnaldo R. Quinones, M.D.

Jag H. Khalsa, Ph.D. Acting Head, Medical Consequences UnitDenise BurnsJag H. Khalsa, Ph.D. Acting Head, Medical Consequences UnitDenise Burns

Office of Extramural AffairsOffice of Extramural AffairsMark Green, Ph.D. Deputy DirectorMark Green, Ph.D. Deputy Director

Office of the DirectorOffice of the DirectorCheryl Kassed, M.S.P.H., Ph.D., Special Assistant to the DirectorHelen Cesari, M.S., Special Assistant to the Deputy DirectorCheryl Kassed, M.S.P.H., Ph.D., Special Assistant to the DirectorHelen Cesari, M.S., Special Assistant to the Deputy Director

NIHNIH

8/8/2019 Volkow204

49/50

NIMHNIMH

NCINCI

NIAIDNIAIDNIAAANIAAA

NINDSNINDS

NICHDNICHD

NIBIBNIBIB

NIDCDNIDCD NHGRINHGRI

NCMHDNCMHD

FICFICNHLBINHLBI

NIANIA

NIAMSNIAMS NIDCRNIDCR

NIDDKNIDDK

NIEHSNIEHS

NEINEI

NIGMSNIGMS

NINRNINR

NCRRNCRR

NCCAMNCCAM

NLMNLM

CITCIT CSRCSR CCCC

NIDANIDA

NIHNIH

8/8/2019 Volkow204

50/50

NIDA-Sponsored Mini-ConventionNIDA-Sponsored Mini-Convention

Cognition &Behavior:Functional Changes in Synaptic Transmission & Drug AbusCognition &Behavior:Functional Changes in Synaptic Transmission & Drug Abuse

Dr. Susan Volman, DNBR, chairDr. Susan Volman, DNBR, chair

Endocannabinoids in the Brain: From Micro to MacroDrs. Yu Lin and Nancy Pilotte, DNBR, co-chairs

Mechanisms of Receptor & Transporter TraffickingDr. Christine Colvis, DNBR, chair

Embryogenesis of Reward-Based BehaviorDr. Robert Riddle, DNBR, chair

Young Investigators: Research & Funding Opportunities at NIDADrs. Susan Volman and Pushpa Thadani, DNBR, co-chairs

Signal Transduction Mechanism in Drug Abuse & AddictionDr. David Shurtleff, DNBR, chair

Neurobiological Mechanisms of Drug & Natural RewardDr. Paul Schnur, DNBR, chair

Endocannabinoids in the Brain: From Micro to MacroDrs. Yu Lin and Nancy Pilotte, DNBR, co-chairs

Mechanisms of Receptor & Transporter TraffickingDr. Christine Colvis, DNBR, chair

Embryogenesis of Reward-Based BehaviorDr. Robert Riddle, DNBR, chair

Young Investigators: Research & Funding Opportunities at NIDADrs. Susan Volman and Pushpa Thadani, DNBR, co-chairs

Signal Transduction Mechanism in Drug Abuse & AddictionDr. David Shurtleff, DNBR, chair

Neurobiological Mechanisms of Drug & Natural RewardDr. Paul Schnur, DNBR, chair

Synaptic Transmission and Excitability: Genetically Encoded Biosensors forDefining Neuronal Circuits and Synaptic ChangeSynaptic Transmission and Excitability: Genetically Encoded Biosensors forDefining Neuronal Circuits and Synaptic Change

Dr. Jonathan Pollock, DNBR, chairDr. Jonathan Pollock, DNBR, chair

volkow204

Documents